Geneva, Oct 5 (UNI) A fourth WHO-prequalified human papillomavirus (HPV) vaccine product, Cecolin, has been confirmed for use in a single-dose schedule to prevent cervical cancer, a statement said.
This important milestone will contribute to improving sustainable supply of HPV vaccines—allowing more girls to be reached with the vaccines that prevent the cancer, the WHO statement said on Friday.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said, “Unlike most other cancers, we have the ability to remove cervical cancer, along with its painful inequities.”